Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Researchers from University College London have discovered that the widely used antiinflammatory drug HUMIRA doesn't just work by inhibiting its target protein, TNF, but by enhancing a particular ...

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

One of the better-quality companies in the pharmaceutical sector, AbbVie ( ABBV 2.35%) had a phenomenal year in 2025.

ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...